Table 1.
Details of cancer genome-wide association studies used in the Mendelian randomisation analysis
| Cancer | Cases | Controls | PubMed ID | No. of contributing studies | GWAS catalogue ID |
|---|---|---|---|---|---|
| Breast | 133384 | 113789 | 32424353 | 82 | GCST010098 GCST010099 GCST010100 |
| Breast triple negative | 2006 | 20815 | |||
| Breast luminal A | 7325 | ||||
| Breast luminal B | 1682 | ||||
| Breast HER2 enriched | 718 | ||||
| Breast HER2 negative luminal B | 1779 | ||||
| Colorectal | 73673 | 86854 | 36539618 | 16 | GCST90129505 |
| Endometrial | 8758 | 46126 | 30093612 | 17 | GCST006465 |
| Lung | 29266 | 56450 | 28604730 | 26 | GCST004744 GCST004746 GCST004747 GCST004748 GCST004749 GCST004750 |
| Lung ever-smoked | 23223 | 16964 | |||
| Lung never-smoked | 2355 | 7504 | |||
| Lung adenocarcinoma | 11273 | 55483 | |||
| Lung squamous cell carcinoma | 7426 | 55627 | |||
| Lung small cell lung cancer | 2664 | 21444 | |||
| Oesophageal | 16790 | 32476 | 35882562 | 5 | NA |
| Ovarian | 26293 | 68502 | 28346442 | 77 | GCST004415 GCST004416 GCST004417 GCST004418 GCST004419 GCST004461 GCST004462 GCST004478 GCST004479 GCST004480 GCST004481 |
| Ovarian invasive high grade serous | 13037 | 40941 | |||
| Ovarian all serous | 16003 | 40941 | |||
| Ovarian invasive mucinous | 1417 | 40941 | |||
| Ovarian all mucinous | 2566 | 40941 | |||
| Ovarian all low malignant potential | 3103 | 40941 | |||
| Ovarian invasive low grade serous and low malignant potential serous | 2966 | 40941 | |||
| Ovarian invasive low grade serous cases | 1012 | 40941 | |||
| Ovarian endometrioid | 2810 | 40941 | |||
| Ovarian clear cell | 1366 | 40941 | |||
| Ovarian low malignant potential serous | 1954 | 40941 | |||
| Ovarian low malignant potential mucinous | 1149 | 40941 | |||
| Prostate | 79194 | 61112 | 29892016 | 8 | GCST006085 |
| Renal | 10784 | 20406 | 28598434 | 5 | GCST004710 |
The number of cases and controls, the number of studies contributing to the meta-analyses and the associated publication and GWAS catalogue IDs are provided for each cancer GWAS. Where applicable, the number of cases and controls in given histological subtypes are also provided.